Ocata Therapeutics, Inc.: 10-Q filed 2014-11-10

Name: Ocata Therapeutics, Inc.: 10-Q filed 2014-11-10
Creator: Ocata Therapeutics, Inc.

What Ocata Therapeutics, Inc. reported in its quarterly report filed 2014-11-10 (fiscal Q3 2014): 37 published measures, 104 facts as tagged in accession 0001019687-14-004157.

This filing

Form: 10-Q (quarterly report)
Filed: 2014-11-10
Fiscal period: fiscal Q3 2014
Accession: 0001019687-14-004157 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Ocata Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2014-09-30	9,247,699	USD
At 2013-12-31	3,907,919	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2014-09-30	8,524,689	USD
At 2013-12-31	26,441,529	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2014-09-30	723,010	USD
At 2013-12-31	-22,533,610	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2014-09-30	7,812,497	USD
At 2013-12-31	1,743,485	USD
At 2013-09-30	5,452,653	USD
At 2012-12-31	7,241,852	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	-3,716,460	USD	92
2014-01-01 to 2014-09-30	-27,924,210	USD	273
2013-07-01 to 2013-09-30	-5,745,735	USD	92
2013-01-01 to 2013-09-30	-19,150,428	USD	273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2014-01-01 to 2014-09-30	135,891	USD	273
2013-01-01 to 2013-09-30	586,091	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2014-09-30	-342,309,490	USD
At 2013-12-31	-313,844,357	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2013-07-01 to 2013-09-30	25,731,913	shares	92
2013-01-01 to 2013-09-30	24,513,912	shares	273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2013-07-01 to 2013-09-30	25,731,913	shares	92
2013-01-01 to 2013-09-30	24,513,912	shares	273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2013-07-01 to 2013-09-30	-0.22	USD/shares	92
2013-01-01 to 2013-09-30	-0.78	USD/shares	273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2013-07-01 to 2013-09-30	-0.22	USD/shares	92
2013-01-01 to 2013-09-30	-0.78	USD/shares	273

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Unit	Days
2014-07-01 to 2014-09-30	USD	92
2014-01-01 to 2014-09-30	USD	273
2013-07-01 to 2013-09-30	USD	92
2013-01-01 to 2013-09-30	USD	273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2014-09-30	780,112	USD
At 2013-12-31	753,576	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	470,653	USD	92
2014-01-01 to 2014-09-30	1,036,859	USD	273
2013-07-01 to 2013-09-30	1,028,243	USD	92
2013-01-01 to 2013-09-30	3,059,298	USD	273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	-3,980,179	USD	92
2014-01-01 to 2014-09-30	-28,115,787	USD	273
2013-07-01 to 2013-09-30	-6,257,907	USD	92
2013-01-01 to 2013-09-30	-17,723,617	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2014-09-30	8,352,711	USD
At 2013-12-31	2,911,859	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	69	USD	92
2014-01-01 to 2014-09-30	429,573	USD	273
2013-07-01 to 2013-09-30	271,021	USD	92
2013-01-01 to 2013-09-30	1,165,438	USD	273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2014-09-30	6,664,602	USD
At 2013-12-31	22,916,789	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2014-09-30	2,183,564	USD
At 2013-12-31	2,285,331	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	4,004,038	USD	92
2014-01-01 to 2014-09-30	28,187,366	USD	273
2013-07-01 to 2013-09-30	6,281,766	USD	92
2013-01-01 to 2013-09-30	17,842,307	USD	273

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	23,859	USD	92
2014-01-01 to 2014-09-30	71,579	USD	273
2013-07-01 to 2013-09-30	23,859	USD	92
2013-01-01 to 2013-09-30	118,690	USD	273

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	15,608	USD	92
2014-01-01 to 2014-09-30	46,825	USD	273
2013-07-01 to 2013-09-30	15,609	USD	92
2013-01-01 to 2013-09-30	66,827	USD	273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	2,415,475	USD	92
2014-01-01 to 2014-09-30	7,641,944	USD	273
2013-07-01 to 2013-09-30	3,061,332	USD	92
2013-01-01 to 2013-09-30	8,668,077	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2014-09-30	34,358,658	shares
At 2013-12-31	26,402,650	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2014-09-30	342,998,141	USD
At 2013-12-31	325,297,736	USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

Period	Value	Unit	Days
At 2014-09-30	1,871,150	USD
At 2013-12-31	1,735,259	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2014-09-30	1,091,038	USD
At 2013-12-31	981,683	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2014-09-30	1,907,858	USD
At 2013-12-31	3,545,713	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2014-09-30	468,538	USD
At 2013-12-31	896,741	USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	-4,388,657	USD	92
2014-01-01 to 2014-09-30	-29,813,402	USD	273
2013-07-01 to 2013-09-30	-6,349,092	USD	92
2013-01-01 to 2013-09-30	-20,909,181	USD	273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	1,588,563	USD	92
2014-01-01 to 2014-09-30	7,076,875	USD	273
2013-07-01 to 2013-09-30	3,220,434	USD	92
2013-01-01 to 2013-09-30	9,174,230	USD	273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	45,013	USD	92
2014-01-01 to 2014-09-30	109,357	USD	273
2013-07-01 to 2013-09-30	26,618	USD	92
2013-01-01 to 2013-09-30	64,320	USD	273

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	221,581	USD	92
2014-01-01 to 2014-09-30	-172,656	USD	273
2013-07-01 to 2013-09-30	19,002	USD	92
2013-01-01 to 2013-09-30	-522,404	USD	273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	263,719	USD	92
2014-01-01 to 2014-09-30	191,577	USD	273
2013-07-01 to 2013-09-30	512,172	USD	92
2013-01-01 to 2013-09-30	-1,426,811	USD	273

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

Period	Value	Unit	Days
2014-01-01 to 2014-09-30	100,793	USD	273
2013-01-01 to 2013-09-30	0	USD	273

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

Period	Value	Unit	Days
2014-01-01 to 2014-09-30	0	USD	273
2013-01-01 to 2013-09-30	0	USD	273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2014-01-01 to 2014-09-30	24,038,191	USD	273
2013-01-01 to 2013-09-30	16,844,532	USD	273

Inspect the source

Entity: Ocata Therapeutics, Inc. / CIK 0001140098
Captured: 2026-09-22 19:40 UTC
SEC response SHA-256: 35ed5f9b7b65d6962e417af6d880d4a32b17c4db50d76618066bbdf10dcb4c40

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001140098.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))